Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2014-01-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/18715206113136660376PMID 24237219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients.

  2013cited by this paper
• The Immunogenicity of the Tumor-Associated Antigen α-Fetoprotein Is Enhanced by a Fusion with a Transmembrane Domain

  2012cited by this paper
• Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

  2012cited by this paper
• Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials.

  2012cited by this paper
• Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

  2012cited by this paper
• Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.

  2012cited by this paper
• Therapeutic cancer vaccines: current status and moving forward.

  2012cited by this paper
• Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

  2011cited by this paper
• A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

  2011cited by this paper
• Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

  2011cited by this paper
• Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer

  2011cited by this paper
• Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.

  2011cited by this paper
• Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.

  2011cited by this paper
• TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy

  2010cited by this paper
• Improved Endpoints for Cancer Immunotherapy Trials

  2010cited by this paper
• Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma.

  2010cited by this paper
• Preclinical Qualification of a New Multi-antigen Candidate Vaccine for Metastatic Melanoma

  2010cited by this paper
• Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice

  2010cited by this paper
• Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model

  2010cited by this paper
• Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

  2009cited by this paper
• The immunologic aspects of poxvirus oncolytic therapy

  2009cited by this paper
• Molecular targets and targeted therapies for malignant mesothelioma.

  2008cited by this paper
• Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.

  2007cited by this paper
• Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated

  2006cited by this paper
• Therapeutic vaccines for prostate cancer.

  2006cited by this paper
• The potential role of fowlpox virus in rational vaccine design

  2006cited by this paper
• Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.

  2006cited by this paper
• Intradermal immune response after infection with Vaccinia virus.

  2006cited by this paper
• Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

  2004cited by this paper
• Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)

  2003cited by this paper
• Vaccine therapy of established tumors in the absence of autoimmunity.

  2003cited by this paper
• Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients

  2003cited by this paper
• A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection.

  2003cited by this paper
• The role of poxviruses in tumor immunotherapy.

  2003cited by this paper
• Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.

  2002cited by this paper
• Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.

  2002cited by this paper
• Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+-T-Cell Populations

  2002cited by this paper
• Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

  2002cited by this paper
• Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

  2002cited by this paper
• Prostate-specific antigen vaccines for prostate cancer

  2002cited by this paper
• Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity.

  2002cited by this paper
• The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.

  2001cited by this paper
• Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.

  2001cited by this paper
• The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.

  2001cited by this paper
• Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen

  2001cited by this paper
• Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

  2000cited by this paper
• Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

  2000cited by this paper
• Immune responses to all ErbB family receptors detectable in serum of cancer patients

  1999cited by this paper
• Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.

  1999cited by this paper
• Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication‐incompetent vaccinia virus encoding MART‐1/Melan‐A 27‐35 epitope

  1997cited by this paper
• Immunization with a Syngeneic Tumor Infected with Recombinant Vaccinia Virus Expressing Granulocyte‐Macrophage Colony‐Stimulating Factor (GM‐CSF) Induces Tumor Regression and Long‐Lasting Systemic Immunity

  1997cited by this paper
• Cancer Gene Therapy Using Tumor Cells Infected with Recombinant Vaccinia Virus Expressing GM-CSF

  1996cited by this paper
• Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

  1996cited by this paper
• Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.

  1994cited by this paper
• Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.

  1994cited by this paper
• Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.

  1993cited by this paper
• Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.

  1992cited by this paper
• Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.

  1992cited by this paper
• Expression of animal virus genomes.

  1971cited by this paper

• Rapid and quantitative evaluation of vaccinia virus‐induced host shutoff using newly generated cell lines stably expressing secreted Gaussia luciferase

  2022cites this paper
• Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures

  2021cites this paper
• Closely related reovirus lab strains induce opposite expression of RIG-I/IFN-dependent versus -independent host genes, via mechanisms of slow replication versus polymorphisms in dsRNA binding σ3 respectively

  2020cites this paper
• Systems vaccinology analysis of a recombinant vaccinia-based vector reveals diverse innate immune signatures at the injection site

  2020cites this paper
• Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells

  2020cites this paper
• Genetic Polymorphisms and Molecular Mechanisms Mediating Oncolytic Potency of Reovirus Strains

  2019cites this paper
• Vaccinia Virus Transcriptome Analysis by RNA Sequencing.

  2019cites this paper
• Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

  2017cites this paper
• Suppression of Poxvirus Replication by Resveratrol

  2017cites this paper
• Immunotherapy: A Future Treatment Modality for Breast Cancer?

  2015cites this paper
• The importance of the tumor microenvironment in the therapeutic management of cancer

  2015cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Enhancing poxvirus vectors vaccine immunogenicity

  2014cites this paper
• Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells

  2014cites this paper
• Editorial: Cancer immunotherapy: does an increasing arsenal of tools point to more fruitful avenues for research?

  2014cites this paper